The RAPID-Elapse study: Can the drug bupropion improve fatigue symptoms in patients with long COVID?

Trial details

Who runs it

Goethe University Frankfurt

Trial code

EU 2025-524443-12-00

Record updated

2026. május 8.

Original description

The primary objectives of the RAPID_ELAPSE trial are hierarchically structured to evaluate the efficacy of bupropion against placebo. The highest priority is to measure the improvement in fatigue severity and incapacitation, assessed by the intra-patient change in the total score of the Fatigue Severity Scale (FSS). Should this endpoint show statistical significance, the analysis proceeds to the second primary objective: assessing the change in the patient's overall physical function using the Short Form-36 Physical Function (SF-36-PF) score.Read full original descriptionShow less

Randomized adaptive assessment of post COVID syndrome treatments (RAPID): Evaluating the Efficacy of Bupropion for the Treatment of Post-COVID-19 Syndrome-associated Fatigue (ELAPSE)

The primary objectives of the RAPID_ELAPSE trial are hierarchically structured to evaluate the efficacy of bupropion against placebo. The highest priority is to measure the improvement in fatigue severity and incapacitation, assessed by the intra-patient change in the total score of the Fatigue Severity Scale (FSS). Should this endpoint show statistical significance, the analysis proceeds to the second primary objective: assessing the change in the patient's overall physical function using the Short Form-36 Physical Function (SF-36-PF) score.

Inclusion: Male or female patient ≥18 years of age; Female patients of childbearing potential, must have a negative pregnancy test at Screening AND agreement of not to attempt to become pregnant AND agreement of not to donate ova AND usage of highly effective forms of birth control; Male patients with female partners of childbearing potential must agree to use adequate barrier contraception (condoms) during treatment with the IMP and for 30 days following the last dose of study medication; Proof of SARS-CoV-2 infection (confirmed by PCR, antigen test, or structured assessment with signed attestation for undocumented positive antigen tests) ≥3 months prior; Fatigue, defined as an FSS (Fatigue Severity Score) ≥45; At least one additional post-COVID symptom, defined as: a) shortness of breath, defined as a mMRC ≥2 b) reduced exercise capacity, defined as <29 repetitions during the 1MSTST c) cognitive impairment, defined as a score of <44 on the written version of the SDMT d) Post-exertional malaise, defined as PEM-Screening positive; Symptom persistence and exclusion of alternative diagnosis: a) Symptoms from inclusion criteria 3 (fatigue) AND 4 (at least one additional symptom) must have persisted for ≥3 months after the initial SARS-CoV-2 infection b) No alternative diagnosis has been identified that better explains the presenting symptoms; Moderate to severe overall disability, defined as a Bell Scale of 20-60; Ability to understand the nature, significance and consequences of the trial and the trial related procedures and to comply with them; Willingness to abstain from changes in the type, dosage, and frequency of concomitant medications through Day 84; Use of a highly effective method of contraception correctly and consistently, as applicable, during trial treatment and for 30 days after the final dose (applicable to individuals of childbearing potential and participating men whose partners may become pregnant).

Exclusion: Planned abrupt discontinuation of alcohol (from >2 standard drinks per day), benzodiazepines, barbiturates, or antiepileptic drugs during the trial period; Ongoing SARS-CoV-2 infection or positive test for SARS-CoV-2 within 14 days prior to enrolment; Participation in any other interventional clinical trial within 30 days before the start of this trial (or 5 half-lives of the investigational product, whichever is longer); Previous enrolment and randomization in this trial; Any concomitant disease significantly impairing assessment of efficacy endpoints, in the opinion of the investigator; Prior history of Postural Orthostatic Tachycardia Syndrome (POTS) or a persistently elevated resting heart rate above 100 beats per minute; Prior history of or ongoing anorexia nervosa, bulimia nervosa, or any malignancy of the central nervous system; Prior history of or ongoing epileptic seizures; Concurrent use of prohibited medications: a) Monoamine oxidase inhibitors (MAOIs): phenelzine, tranylcypromine, selegiline, rasagiline, isocarboxazid, linezolid, methylene blue IV b) Other bupropion-containing products: Zyban®, Elontril®, or any generic bupropion formulation c) Selective serotonergic drugs: SSRIs (e.g., sertraline, fluoxetine, paroxetine, citalopram, escitalopram), SNRIs (e.g., venlafaxine, duloxetine, desvenlafaxine) d) Drugs metabolized by or influencing CYP2D6: tamoxifen, antiarrhythmics (flecainide, propafenone), beta-blockers (metoprolol, carvedilol, timolol), antipsychotics (risperidone, aripiprazole, perphenazine), codeine, tramadol, dextromethorphan, atomoxetine, efavirenz, ritonavir, clopidogrel, ticlopidine e) Drugs lowering seizure threshold: antipsychotics (clozapine, olanzapine, quetiapine, haloperidol, chlorpromazine), quinolone antibiotics (ciprofloxacin, levofloxacin, moxifloxacin), tramadol and tapentadol, sedating antihistamines (diphenhydramine, high-dose hydroxyzine), tricyclic antidepressants (amitriptyline, imipramine), antimalarials (chloroquine, mefloquine), theophylline, high-dose systemic corticosteroids, stimulants (methylphenidate, amphetamines) f) Prohibited medications must be discontinued ≥14 days prior to enrolment; Positive urine drug screen at screening for non-prescribed substances of abuse (amphetamines, cocaine, opioids, benzodiazepines); Uncontrolled hypertension: Systolic BP ≥160 mmHg and/or diastolic BP ≥100 mmHg at screening (average of ≥2 measurements after 5 minutes of rest, on two separate occasions if initial reading elevated); Active major psychiatric illness that cannot be adequately controlled, defined as: a) Schizophrenia, schizoaffective disorder, or depression with psychotic features (psychiatric hospitalization within past 12 months, OR dose adjustment of antipsychotic within past 3 months, OR current active hallucinations or delusions), OR b) Bipolar disorder (psychiatric hospitalization for mania/hypomania within past 12 months, OR dose adjustment of mood stabilizer within past 3 months, OR current manic/hypomanic/mixed episode), OR c) Severe depression (PHQ-9 >25 with psychiatric hospitalization within past 6 months, OR initiation/dose adjustment of antidepressant within past 6 weeks, OR clinical deterioration requiring urgent psychiatric intervention); History of suicide attempt within the past 12 months, OR current suicidal ideation (PHQ-9 item 9 score ≥2); Evidence of currently active malignancy (primary tumor or metastases) of any organ system (excluding localized basal cell carcinoma of the skin or adequately treated cervical cancer); Pre-COVID history of chronic fatigue syndrome (CFS/ME) or other fatigue syndromes due to associated diseases (e.g., cancer-related fatigue, autoimmune disease-associated fatigue); Known hypersensitivity or intolerance to bupropion; Current moderate or severe substance use disorder without documented abstinence for at least 6 months; Hepatic impairment: a) Severe liver cirrhosis (Child-Pugh Class C), OR b) ALT or AST >3× ULN at screening, OR c) Total bilirubin >2× ULN at screening (excluding Gilbert's syndrome), OR d) ALT or AST >3× ULN with total bilirubin >1.5× ULN; Renal impairment: a) eGFR <30 mL/min/1.73 m² (CKD stage 4-5) at screening (calculated using CKD-EPI equation), OR b) End-stage renal disease requiring hemodialysis or peritoneal dialysis, OR c) Serum creatinine increase ≥2-fold from baseline within 7 days prior to screening, OR d) Acute decline in renal function requiring urgent intervention; Electrolyte imbalance: a) Sodium <130 mmol/L or >150 mmol/L, OR b) Potassium <3.0 mmol/L or >5.5 mmol/L; Severe cardiovascular disease: a) Severe heart failure (NYHA Class III-IV), OR b) Clinically significant arrhythmias (uncontrolled atrial fibrillation with ventricular rate >100 bpm, documented ventricular tachycardia/fibrillation, requiring antiarrhythmic medication or cardiac device), OR c) QTc prolongation (>480 ms on screening ECG), OR d) Brugada syndrome, OR e) Recent myocardial infarction (within past 6 months), OR f) Unstable angina (angina at rest or with minimal activity, new-onset severe angina within 2 months, crescendo angina, or hospitalization for angina within past 3 months), OR g) Cardiomyopathy with LVEF <40%; Known or planned pregnancy or currently breastfeeding; Known ongoing or planned intake of bupropion-containing products (Zyban®, Elontril®, or any generic bupropion formulation); Simultaneous participation in other interventional trials which could interfere with this trial (Note: simultaneous participation in non-interventional registry and diagnostic trials is permitted); Patient without legal capacity who is unable to understand the nature, significance, and consequences of the trial; Person who is in a relationship of dependence or employment with the sponsor or the investigator; Persons deprived of liberty or placed in an institution by judicial or administrative order.

EU CTIS 2025-524443-12-00